Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer

British Journal of Cancer

Volumn 76, Issue 6, 1997, Pages 760-764

  Aruga, A ^a   Koizumi, M ^a   Hotta, R ^a   Takahashi, S ^a   Ogata, E ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

BAL; Bone metastasis; fDPD; ICTP; Lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PEPTIDE;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PATIENT MONITORING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 0030821404     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.458     Document Type: Article

References (13)

1. Abrams HL, Spiro R and Goldstein N (1950) Metastasis in carcinomas: analysis of 1000 autopsied cases. Cancer 3: 74-85
2. Blomqvist C, Risteli L, Virkkunen P, Sarna S and Elomaa I (1996) Markers of type 1 collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 73: 1074-1079
3. Coleman RH, Houston S, James I, Rodger A, Rubens RD, Leonard RCF and Ford J (1992). Preliminary results of use of urinary excretion of pyridinium crosslinks for monitoring metastatic disease. Br J Cancer 65: 766-768
4. Elomaa I, Virkkunen P, Risteli L and Risteli J (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66: 337-341
5. Garnero P, Gineyts E, Riou JP and Dermas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79: 780-785
6. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, Yamashita T, Maeda H, Takahashi S, Aiba K and Ogata E (1995) Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 121: 542-548
7. Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T and Ogata E (1997) Dissociation of bone formation markers in hone metastasis of prostate cancer. Br J Cancer 75: 1601-1604
8. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M and Elomaa I (1995) Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061-1064
9. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T and Ogata E (1997) Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157: 539-543
10. Miyamoto KK, McSherry SA, Robins SP, Besterman JM and Mohler JL (1994) Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151: 909-913
11. Napoli LD, Hansen HH, Muggia FM and Twigg HL (1973) The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 108: 17-21
12. Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M and Inoue T (1994) Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer 70: 701-703
13. Tubiana-Hulin M (1991) Incidence, prevalence and distribution of hone metastases. Bone 12(suppl. 1): S9-S10